New hope for tough pancreatic cancers: experimental combo therapy trial opens
NCT ID NCT07342725
Summary
This study is testing whether adding an experimental immunotherapy drug called IBI363 to standard chemotherapy helps people with advanced pancreatic cancer that has worsened after initial treatment. About 48 patients whose cancer has spread or cannot be surgically removed will receive the combination treatment. Researchers will monitor how well the treatment works and check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.